Compare AFG & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFG | KRYS |
|---|---|---|
| Founded | 1872 | 2015 |
| Country | United States | United States |
| Employees | 8500 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 10.3B |
| IPO Year | N/A | 2017 |
| Metric | AFG | KRYS |
|---|---|---|
| Price | $143.43 | $335.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $141.00 | ★ $297.60 |
| AVG Volume (30 Days) | 385.2K | ★ 531.0K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | N/A | $38.74 |
| Revenue Next Year | $4.44 | $32.53 |
| P/E Ratio | ★ $12.86 | $178.69 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $122.11 | $130.50 |
| 52 Week High | $150.02 | $382.54 |
| Indicator | AFG | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 59.56 | 43.97 |
| Support Level | $128.04 | $246.17 |
| Resistance Level | $144.74 | $382.33 |
| Average True Range (ATR) | 2.52 | 17.52 |
| MACD | -0.22 | -5.71 |
| Stochastic Oscillator | 73.51 | 21.50 |
American Financial Group Inc is an insurance holding company. Through its subsidiaries, it is engaged in the property and casualty insurance business, focusing on specialized commercial products for businesses. The group operates through two segments: Property and Casualty Insurance, which generates maximum revenue, and Other. The Property and Casualty Insurance segment is further divided into different sub-segments, such as Property and transportation, Specialty casualty, and Specialty financial. These sub-segments offer insurance coverage for vehicles and commercial property, customized programs for small to mid-sized businesses, workers' compensation insurance, risk management insurance programs for lending and leasing institutions, trade credit insurance, and other insurance products.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.